JP2016503026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503026A5 JP2016503026A5 JP2015547985A JP2015547985A JP2016503026A5 JP 2016503026 A5 JP2016503026 A5 JP 2016503026A5 JP 2015547985 A JP2015547985 A JP 2015547985A JP 2015547985 A JP2015547985 A JP 2015547985A JP 2016503026 A5 JP2016503026 A5 JP 2016503026A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- injectable composition
- anthracycline compound
- reconstituted formulation
- reconstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 53
- 239000007972 injectable composition Substances 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 238000009472 formulation Methods 0.000 claims description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 206010039491 Sarcoma Diseases 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 12
- 201000002528 pancreatic cancer Diseases 0.000 claims description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 12
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 11
- OBMJQRLIQQTJLR-USGQOSEYSA-N n-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)CCCCCN1C(C=CC1=O)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OBMJQRLIQQTJLR-USGQOSEYSA-N 0.000 claims description 8
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 6
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000008383 Wilms tumor Diseases 0.000 claims description 6
- 201000002454 adrenal cortex cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 210000004907 gland Anatomy 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims description 5
- 208000022013 kidney Wilms tumor Diseases 0.000 claims description 5
- 201000008026 nephroblastoma Diseases 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000013022 formulation composition Substances 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737003P | 2012-12-13 | 2012-12-13 | |
| US61/737,003 | 2012-12-13 | ||
| PCT/US2013/075002 WO2014093815A1 (en) | 2012-12-13 | 2013-12-13 | Anthracycline formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018145172A Division JP6833768B2 (ja) | 2012-12-13 | 2018-08-01 | アントラサイクリン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503026A JP2016503026A (ja) | 2016-02-01 |
| JP2016503026A5 true JP2016503026A5 (enExample) | 2017-01-19 |
| JP6433913B2 JP6433913B2 (ja) | 2018-12-05 |
Family
ID=50934989
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547985A Active JP6433913B2 (ja) | 2012-12-13 | 2013-12-13 | アントラサイクリン製剤 |
| JP2018145172A Active JP6833768B2 (ja) | 2012-12-13 | 2018-08-01 | アントラサイクリン製剤 |
| JP2019147584A Withdrawn JP2019206583A (ja) | 2012-12-13 | 2019-08-09 | アントラサイクリン製剤 |
| JP2021085891A Active JP7213303B2 (ja) | 2012-12-13 | 2021-05-21 | アントラサイクリン製剤 |
| JP2021085892A Pending JP2021120415A (ja) | 2012-12-13 | 2021-05-21 | アントラサイクリン製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018145172A Active JP6833768B2 (ja) | 2012-12-13 | 2018-08-01 | アントラサイクリン製剤 |
| JP2019147584A Withdrawn JP2019206583A (ja) | 2012-12-13 | 2019-08-09 | アントラサイクリン製剤 |
| JP2021085891A Active JP7213303B2 (ja) | 2012-12-13 | 2021-05-21 | アントラサイクリン製剤 |
| JP2021085892A Pending JP2021120415A (ja) | 2012-12-13 | 2021-05-21 | アントラサイクリン製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20150342975A1 (enExample) |
| EP (2) | EP3915369A1 (enExample) |
| JP (5) | JP6433913B2 (enExample) |
| AU (1) | AU2013359048A1 (enExample) |
| CA (1) | CA2894548C (enExample) |
| DK (1) | DK2931042T3 (enExample) |
| WO (1) | WO2014093815A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6433913B2 (ja) * | 2012-12-13 | 2018-12-05 | サイトレックス コーポレイション | アントラサイクリン製剤 |
| NZ631022A (en) | 2013-06-05 | 2018-05-25 | Cytrx Corp | Cytotoxic agents for the treatment of cancer |
| AU2016311444B2 (en) | 2015-08-25 | 2019-02-07 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
| US11071812B2 (en) * | 2016-05-31 | 2021-07-27 | Penumbra, Inc. | Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood |
| KR20220068272A (ko) | 2017-08-15 | 2022-05-25 | 난트셀, 인크. | Hank 세툭시맙 조합 및 방법 |
| WO2020081174A1 (en) | 2018-10-16 | 2020-04-23 | Nant Holdings Ip, Llc | Alpha emitter compositions and methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| JP2915252B2 (ja) | 1993-06-30 | 1999-07-05 | 明治製菓株式会社 | 溶解性が改善された製剤の製造法 |
| BR9713661A (pt) * | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulação e método para o tratamento de neoplasmas por inalação |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
| EP1337273A2 (en) * | 2000-11-28 | 2003-08-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| JP5634862B2 (ja) * | 2007-05-16 | 2014-12-03 | カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低粘度アントラサイクリン製剤 |
| EP2216049A1 (en) * | 2009-02-06 | 2010-08-11 | Freie Universität Berlin | Drug conjugates with polyglycerols |
| RU2531591C2 (ru) * | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
| JP6433913B2 (ja) * | 2012-12-13 | 2018-12-05 | サイトレックス コーポレイション | アントラサイクリン製剤 |
-
2013
- 2013-12-13 JP JP2015547985A patent/JP6433913B2/ja active Active
- 2013-12-13 AU AU2013359048A patent/AU2013359048A1/en not_active Abandoned
- 2013-12-13 EP EP21169873.3A patent/EP3915369A1/en active Pending
- 2013-12-13 DK DK13863251.8T patent/DK2931042T3/da active
- 2013-12-13 EP EP13863251.8A patent/EP2931042B1/en active Active
- 2013-12-13 WO PCT/US2013/075002 patent/WO2014093815A1/en not_active Ceased
- 2013-12-13 CA CA2894548A patent/CA2894548C/en active Active
- 2013-12-13 US US14/651,898 patent/US20150342975A1/en not_active Abandoned
-
2017
- 2017-05-09 US US15/590,331 patent/US10328093B2/en active Active
-
2018
- 2018-08-01 JP JP2018145172A patent/JP6833768B2/ja active Active
-
2019
- 2019-08-09 JP JP2019147584A patent/JP2019206583A/ja not_active Withdrawn
-
2021
- 2021-05-21 JP JP2021085891A patent/JP7213303B2/ja active Active
- 2021-05-21 JP JP2021085892A patent/JP2021120415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2021128415A (ru) | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения | |
| JP2012158602A5 (enExample) | ||
| RU2013120311A (ru) | Терапевтическое применение агониста tlr и комбинированная терапия | |
| JP2016506916A5 (enExample) | ||
| RU2012131663A (ru) | Композиции и способы лечения рака яичников | |
| JP2017533223A5 (enExample) | ||
| JP2019521180A5 (enExample) | ||
| JP2015535243A5 (enExample) | ||
| RU2015134583A (ru) | Фармацевтические композиции, содержащие доноры нитроксила | |
| EP4736953A2 (en) | Therapeutic agents and methods | |
| JP2015502926A5 (enExample) | ||
| RU2010140890A (ru) | Улучшенные способы противоопухолевого лечения | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| RU2014101036A (ru) | Стабилизированная композиция вориконазола | |
| JP2017514854A5 (enExample) | ||
| JP2014530181A5 (enExample) | ||
| SG194735A1 (en) | Compositions and methods for treating cancer | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| CN105283456B (zh) | 5-溴-靛玉红 | |
| EA201390716A1 (ru) | Комбинированная терапия внеклеточным доменом fgfr1 | |
| JP2021511344A5 (enExample) | ||
| JP2015528802A5 (enExample) | ||
| Woo et al. | Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis | |
| Tazi et al. | Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma |